WEBVTT

00:00:08.000 --> 00:00:11.837
<v Megan Wetzel>Hi everyone, I am Megan Wetzel, and I am
the vice president of our access and</v>

00:00:11.837 --> 00:00:15.925
<v Megan Wetzel>affordability solutions here at Cover My
Meds. Today I'm excited to be joined by a</v>

00:00:15.925 --> 00:00:19.863
<v Megan Wetzel>group of exceptional leaders that each
bring a different perspective across the</v>

00:00:19.863 --> 00:00:23.800
<v Megan Wetzel>portfolio here from Cover My Meds. We're
digging into what's next in medication</v>

00:00:23.800 --> 00:00:27.385
<v Megan Wetzel>access and affordability and why
traditional ways of thinking won't keep</v>

00:00:27.385 --> 00:00:29.000
<v Megan Wetzel>pace where the market is headed.</v>

00:00:29.000 --> 00:00:32.789
<v Megan Wetzel>Because the reality is a coverage approval
isn't the finish line, right? It's just</v>

00:00:32.789 --> 00:00:36.719
<v Megan Wetzel>the beginning for a patient's journey. And
too often, patients still don't make it to</v>

00:00:36.719 --> 00:00:40.462
<v Megan Wetzel>therapy based on the barriers that they
face. The Cover My Meds medication access</v>

00:00:40.462 --> 00:00:44.205
<v Megan Wetzel>report highlights that 65% of patients
experience some kind of delay in accessing</v>

00:00:44.205 --> 00:00:45.000
<v Megan Wetzel>their medication.</v>

00:00:45.000 --> 00:00:49.343
<v Megan Wetzel>This translates directly into lost therapy
starts, frustrated care teams at the</v>

00:00:49.343 --> 00:00:54.021
<v Megan Wetzel>detriment of brand performance. What we've
known as this traditional access playbook,</v>

00:00:54.021 --> 00:00:58.364
<v Megan Wetzel>formulary placement, copay cards, field
team support, it just isn't enough when</v>

00:00:58.364 --> 00:01:02.318
<v Megan Wetzel>market expectations are changing
constantly. The patient journey is even</v>

00:01:02.318 --> 00:01:06.828
<v Megan Wetzel>more fragmented than it used to be, and
care teams are working across systems that</v>

00:01:06.828 --> 00:01:09.000
<v Megan Wetzel>just don't communicate with each other.</v>

00:01:09.000 --> 00:01:13.034
<v Megan Wetzel>Not to mention, most brand teams are
trying to solve these challenges without</v>

00:01:13.034 --> 00:01:17.385
<v Megan Wetzel>access to a network that's already active
across providers, pharmacies, and payers.</v>

00:01:17.385 --> 00:01:21.260
<v Megan Wetzel>When you look at the access environment
today, what are the most important</v>

00:01:21.260 --> 00:01:24.975
<v Megan Wetzel>pressure points for biopharma? Where are
brands losing ground between a</v>

00:01:24.975 --> 00:01:28.000
<v Megan Wetzel>prescription being written and a patient
starting therapy?</v>

00:01:28.000 --> 00:01:31.918
<v Dimple Patel>We often hear that providers and their
staff, we are working across 9 different</v>

00:01:31.918 --> 00:01:35.836
<v Dimple Patel>platforms just to process a single PA
request, and that's really creating a lot</v>

00:01:35.836 --> 00:01:39.753
<v Dimple Patel>of complexity. We at Cover My Meds are so
passionate about trying to solve this</v>

00:01:39.753 --> 00:01:43.671
<v Dimple Patel>problem and really creating a system
that's more connected and seamless. At the</v>

00:01:43.671 --> 00:01:46.986
<v Dimple Patel>pharmacy counter when that script is
rejected, we can start a prior</v>

00:01:46.986 --> 00:01:50.000
<v Dimple Patel>authorization and send it right into the
provider's workflow.</v>

00:01:50.000 --> 00:01:54.518
<v Dimple Patel>They can process that request and
ultimately submissions and approved claims</v>

00:01:54.518 --> 00:01:59.398
<v Dimple Patel>can start to go up and I think that we're
really focused on not just building that</v>

00:01:59.398 --> 00:02:03.735
<v Dimple Patel>connected network but also creating
real-time insights for pharma further</v>

00:02:03.735 --> 00:02:08.735
<v Dimple Patel>upstream so that they can react to market
events quickly and in a consistent way. We</v>

00:02:08.735 --> 00:02:10.000
<v Dimple Patel>can't always control.</v>

00:02:10.000 --> 00:02:14.753
<v Dimple Patel>How a brand is going to perform in the
market from growth through maturity, but</v>

00:02:14.753 --> 00:02:19.627
<v Dimple Patel>what a brand can control is working with a
partner that has the infrastructure in</v>

00:02:19.627 --> 00:02:24.563
<v Dimple Patel>place where they can quickly respond to
market events and make sure that messaging</v>

00:02:24.563 --> 00:02:27.000
<v Dimple Patel>is going out consistently for providers.</v>

00:02:27.000 --> 00:02:31.078
<v Shae Scott>When I think back to when I was a
pharmacist working behind the counter in</v>

00:02:31.078 --> 00:02:35.045
<v Shae Scott>the pharmacy, we would see prior
authorization requests all the time. We</v>

00:02:35.045 --> 00:02:39.291
<v Shae Scott>would work with the providers, get it
approved, and see a paid claim. We'd be</v>

00:02:39.291 --> 00:02:43.704
<v Shae Scott>excited, but then only to find out that
the patient can't afford the medication,</v>

00:02:43.704 --> 00:02:47.000
<v Shae Scott>right? And so now we're taking the extra
time to figure out.</v>

00:02:47.000 --> 00:02:51.484
<v Shae Scott>What do we need to do to get them on
therapy quicker? And by this time, two to</v>

00:02:51.484 --> 00:02:56.258
<v Shae Scott>three weeks may have passed. And so we've
delayed the patient getting on treatment.</v>

00:02:56.258 --> 00:03:00.625
<v Shae Scott>So, the real value of connecting the
upstream visibility with the downstream</v>

00:03:00.625 --> 00:03:04.934
<v Shae Scott>intervention is just getting that patient
to start therapy quicker. Support</v>

00:03:04.934 --> 00:03:09.651
<v Shae Scott>shouldn't start at the pharmacy. It should
begin prior to the patient even getting</v>

00:03:09.651 --> 00:03:10.000
<v Shae Scott>there.</v>

00:03:10.000 --> 00:03:15.338
<v Shae Scott>For the brand, so this is a mind shift
change, right? It's going from a reactive</v>

00:03:15.338 --> 00:03:20.676
<v Shae Scott>rescue to a proactive redesign of the
programs. And that's what I'm really proud</v>

00:03:20.676 --> 00:03:25.000
<v Shae Scott>about what we're doing at Cover My Meds by
being able to connect.</v>

00:03:25.000 --> 00:03:29.982
<v Shae Scott>The three players, the pharmacies, payers
and the providers, and getting quicker</v>

00:03:29.982 --> 00:03:32.000
<v Shae Scott>start to therapies for patients.</v>

00:03:32.000 --> 00:03:35.860
<v Megan Wetzel>That's really the through line here in all
of this, right? Like the through line here</v>

00:03:35.860 --> 00:03:39.629
<v Megan Wetzel>is that these are connected moments in the
same journey. So one of these breakdowns</v>

00:03:39.629 --> 00:03:43.259
<v Megan Wetzel>is going to cause a patient to not have
the ability to get on therapy. And we're</v>

00:03:43.259 --> 00:03:46.982
<v Megan Wetzel>kind of building on this idea of what an
ultimately connected infrastructure looks</v>

00:03:46.982 --> 00:03:50.612
<v Megan Wetzel>like. So I'd love to continue to build on
this with you all and think about what</v>

00:03:50.612 --> 00:03:54.426
<v Megan Wetzel>this could mean from a system perspective
and describing a system that is ultimately</v>

00:03:54.426 --> 00:03:57.000
<v Megan Wetzel>connected. So Tate, I'm gonna start with
you on this one.</v>

00:03:57.000 --> 00:04:01.258
<v Tate Williams>So that's what I love about what this
connected world can look like and what</v>

00:04:01.258 --> 00:04:05.515
<v Tate Williams>we're doing here at Cover My Meds is
really starting to connect this all the</v>

00:04:05.515 --> 00:04:10.170
<v Tate Williams>way through so that, OK, I've got a prior
auth in place, a patient has a rejection,</v>

00:04:10.170 --> 00:04:14.882
<v Tate Williams>boom, I'm starting that prior auth and I'm
starting to get that worked with the doc.</v>

00:04:14.882 --> 00:04:19.367
<v Tate Williams>OK, I've also got a cash plan in place for
those patients so that they can start</v>

00:04:19.367 --> 00:04:23.000
<v Tate Williams>therapy. They can get on, make sure that
it's treating what they.</v>

00:04:23.000 --> 00:04:27.676
<v Tate Williams>Need to be treated and then ultimately
start to pull it through once that PA's</v>

00:04:27.676 --> 00:04:32.534
<v Tate Williams>worked, boom, copay assistance is there,
and we're able to really tell that fully</v>

00:04:32.534 --> 00:04:36.846
<v Tate Williams>connected story for our biopharma
partners. It's really a differentiator</v>

00:04:36.846 --> 00:04:38.000
<v Tate Williams>that we have today.</v>

00:04:38.000 --> 00:04:42.810
<v Dimple Patel>I think it's so important when we're
considering that the prior authorization</v>

00:04:42.810 --> 00:04:47.873
<v Dimple Patel>decision making process is really being
pulled upstream into the EHR workflow. So</v>

00:04:47.873 --> 00:04:53.000
<v Dimple Patel>in many cases, providers are learning in
real time when a claim is being rejected.</v>

00:04:53.000 --> 00:04:57.587
<v Dimple Patel>And they know that they have to overcome
this challenge often before the patient</v>

00:04:57.587 --> 00:05:02.000
<v Dimple Patel>even leaves the office. So I think it's a
really underutilized insight today.</v>

00:05:02.000 --> 00:05:06.688
<v Shae Scott>When prior authorization, affordability,
support, and claim level intervention are</v>

00:05:06.688 --> 00:05:11.434
<v Shae Scott>all designed to work together, brands can
see a lot more value because they can see</v>

00:05:11.434 --> 00:05:16.238
<v Shae Scott>more predictable starts, and that's really
where the value comes from for biopharma,</v>

00:05:16.238 --> 00:05:20.000
<v Shae Scott>and that's where we at Cover My Meds can
really help support them.</v>

00:05:20.000 --> 00:05:24.190
<v Megan Wetzel>We can't have a strategy conversation
about access and affordability without</v>

00:05:24.190 --> 00:05:28.212
<v Megan Wetzel>touching on AI and automation. So the
question I know for biopharma isn't</v>

00:05:28.212 --> 00:05:30.000
<v Megan Wetzel>whether to utilize AI, it's how.</v>

00:05:30.000 --> 00:05:34.981
<v Dimple Patel>AI is different. It is learning based on
much larger data sets, and it's really</v>

00:05:34.981 --> 00:05:40.282
<v Dimple Patel>identifying patterns that rules-based data
would not be able to see in real time. So</v>

00:05:40.282 --> 00:05:45.391
<v Dimple Patel>we can take that information and start to
design programs based on signals before</v>

00:05:45.391 --> 00:05:50.308
<v Dimple Patel>they become patterns, and I think that
this is so critical to think about when</v>

00:05:50.308 --> 00:05:55.290
<v Dimple Patel>you're selecting a vendor to work with
because you have to think about the data</v>

00:05:55.290 --> 00:06:00.271
<v Dimple Patel>model that that AI is learning from. At
Cover My Meds, we are working with over</v>

00:06:00.271 --> 00:06:05.188
<v Dimple Patel>50,000 pharmacies and over a million
providers, and we can really start to see</v>

00:06:05.188 --> 00:06:10.170
<v Dimple Patel>some of those shifts in market events
before they become major follow-up points</v>

00:06:10.170 --> 00:06:11.000
<v Dimple Patel>for patients.</v>

00:06:11.000 --> 00:06:15.577
<v Shae Scott>The automation of the pharmacy can only be
as smart as the data that it's connected</v>

00:06:15.577 --> 00:06:20.209
<v Shae Scott>to. And once you connect the two together,
the automation and the data, that's where</v>

00:06:20.209 --> 00:06:24.340
<v Shae Scott>we start seeing a lot more value in the
programs that we offer. The pace of</v>

00:06:24.340 --> 00:06:29.028
<v Shae Scott>possibility is so key right here, and that
real-time data can really help provide the</v>

00:06:29.028 --> 00:06:32.935
<v Shae Scott>support and change that support to
actually make it more actionable. So</v>

00:06:32.935 --> 00:06:35.000
<v Shae Scott>that's really what I'm excited about.</v>

00:06:35.000 --> 00:06:38.830
<v Megan Wetzel>It's clear to me that across all of these
perspectives, access is only effective at</v>

00:06:38.830 --> 00:06:42.473
<v Megan Wetzel>scale of all things that work together.
Prior authorization, affordability, and</v>

00:06:42.473 --> 00:06:46.069
<v Megan Wetzel>claims. When we're able to connect those
three things together, we're reducing</v>

00:06:46.069 --> 00:06:49.946
<v Megan Wetzel>barriers and creating those outcomes that
biopharma is looking for. That's the shift</v>

00:06:49.946 --> 00:06:53.869
<v Megan Wetzel>that we're doing here at Cover My Meds. We
are helping BioPharma turn these solutions</v>

00:06:53.869 --> 00:06:57.186
<v Megan Wetzel>from point solutions to integrated
connected solutions. I wanna thank my</v>

00:06:57.186 --> 00:07:01.016
<v Megan Wetzel>presenters today. Thank you, Dimple. Thank
you, Shae. Thank you, Tate for providing</v>

00:07:01.016 --> 00:07:04.472
<v Megan Wetzel>your unique perspectives across the
portfolio today. And I just want to end</v>

00:07:04.472 --> 00:07:08.255
<v Megan Wetzel>with one thing that's clear. Cover My Meds
truly is the end to end partner that is</v>

00:07:08.255 --> 00:07:11.758
<v Megan Wetzel>connecting all of these solutions on
behalf of BioPharma, and I'm excited to</v>

00:07:11.758 --> 00:07:14.000
<v Megan Wetzel>see where access and affordability takes
us next.</v>
